Model validation: acute effects of gamma-secretase inhibitor DAPT in APP-London mice

To date, no clinically proven anti-Alzheimer disease-modifying molecules are available that could be used for validating animal models of the disease. Where possible, however, we use reference compounds for examining the therapeutic window when targeting specific disease-related processes in our transgenic models.

Check out the acute effect of a gamma-secretase inhibitor DAPT on (oligomeric) Abeta levels in brain and CSF of 4-5 month old APP-London mice.